tradingkey.logo

Myriad Genetics Inc

MYGN
查看詳細走勢圖
6.550USD
-0.010-0.15%
收盤 12/24, 13:00美東報價延遲15分鐘
609.80M總市值
虧損本益比TTM

Myriad Genetics Inc

6.550
-0.010-0.15%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.15%

5天

-4.80%

1月

-11.25%

6月

+34.77%

今年開始到現在

-52.22%

1年

-52.01%

查看詳細走勢圖

TradingKey Myriad Genetics Inc股票評分

單位: USD 更新時間: 2025-12-23

操作建議

Myriad Genetics Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名92/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價8.06。中期看,股價處於平穩狀態。近一個月,市場表現非常差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Myriad Genetics Inc評分

相關信息

行業排名
92 / 208
全市場排名
221 / 4568
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 13 分析師
持有
評級
8.064
目標均價
+14.05%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Myriad Genetics Inc亮點

亮點風險
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
業績高增長
公司營業收入穩步增長,連續3年增長23.47%
估值高估
公司最新PE估值-1.51,處於3年歷史高位
機構減倉
最新機構持股92.00M股,環比減少10.78%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉21.15K股
活躍度增加
近期活躍度增加,過去20天平均換手率1.07

Myriad Genetics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Myriad Genetics Inc簡介

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
公司代碼MYGN
公司Myriad Genetics Inc
CEORaha (Samraat S)
網址https://myriad.com/

常見問題

Myriad Genetics Inc(MYGN)的當前股價是多少?

Myriad Genetics Inc(MYGN)的當前股價是 6.550。

Myriad Genetics Inc 的股票代碼是什麼?

Myriad Genetics Inc的股票代碼是MYGN。

Myriad Genetics Inc股票的52週最高點是多少?

Myriad Genetics Inc股票的52週最高點是15.470。

Myriad Genetics Inc股票的52週最低點是多少?

Myriad Genetics Inc股票的52週最低點是3.760。

Myriad Genetics Inc的市值是多少?

Myriad Genetics Inc的市值是609.80M。

Myriad Genetics Inc的淨利潤是多少?

Myriad Genetics Inc的淨利潤為-127.30M。

現在Myriad Genetics Inc(MYGN)的股票是買入、持有還是賣出?

根據分析師評級,Myriad Genetics Inc(MYGN)的總體評級為持有,目標價格為8.064。

Myriad Genetics Inc(MYGN)股票的每股收益(EPS TTM)是多少

Myriad Genetics Inc(MYGN)股票的每股收益(EPS TTM)是-4.347。
KeyAI